会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Oxyindole derivatives
    • 氧吲哚衍生物
    • US20060194842A1
    • 2006-08-31
    • US11360095
    • 2006-02-22
    • Chikara UchidaHiroki SoneKiyoshi Kawamura
    • Chikara UchidaHiroki SoneKiyoshi Kawamura
    • A61K31/454C07D417/14C07D413/14C07D403/14
    • C07D401/12C07D401/14C07D405/14
    • This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, R1, R2, R3, R4 and R5 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes or apnea syndrome.
    • 本发明涉及式(I)化合物或其药学上可接受的盐,其中:A,R 1,R 2,R 3, SUP,R 4和R 5各自如本文所述或其药学上可接受的盐,以及含有这些化合物的组合物和这些化合物在治疗病症中的用途 由5-HT 4激动剂活性介导,例如但不限于胃食管反流疾病,胃肠道疾病,胃动力障碍,非溃疡性消化不良,功能性消化不良,肠易激综合征(IBS), 便秘,消化不良,食管炎,胃食管疾病,恶心,中枢神经系统疾病,阿尔茨海默病,认知障碍,呕吐,偏头痛,神经系统疾病,疼痛,心血管疾病,心力衰竭,心律失常,糖尿病或呼吸暂停综合征。
    • 5. 发明授权
    • Quinolonecarboxylic acid compounds having 5-HT4 receptor agonistic activity
    • 具有5-HT 4受体激动活性的喹诺酮羧酸化合物
    • US07964727B2
    • 2011-06-21
    • US10595948
    • 2004-11-10
    • Tomoki KatoKiyoshi KawamuraMikio MoritaChikara Uchida
    • Tomoki KatoKiyoshi KawamuraMikio MoritaChikara Uchida
    • C07D221/02C07D215/00C07D413/00A01N43/40A01N43/42A61K31/435A61K31/44
    • C04B35/632C07D401/12C07D401/14C07D405/14
    • This invention provides a compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of substituents α1; A represents an alkylene group having from 1 to 4 carbon atoms; B represents a covalent bond or an alkylene group having from 1 to 5 carbon atoms; R1 represents an isopropyl group, a n-propyl group or a cyclopentyl group; R2 represents a methyl group, a fluorine atom or a chlorine atom; R3 independently represents (i) an oxo group, a hydroxy group, an amino group, an alkylamino group or a carboxyl group; (ii) a cycloalkyl group having from 3 to 8 carbon atoms, and said cycloalkyl group being substituted by 1 to 5 substituents, or (iii) a heterocyclic group having from 3 to 8 atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 5 substituents, and n is 1, 2 or 3, or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.
    • 本发明提供式(I)化合物:其中Het表示具有一个氮原子的杂环基团,B直接与该碳原子结合,并且具有4至7个碳原子,所述杂环基团未被取代或被1至4个取代基取代 独立地选自取代基α1; A表示具有1至4个碳原子的亚烷基; B表示共价键或具有1至5个碳原子的亚烷基; R1表示异丙基,正丙基或环戊基; R2表示甲基,氟原子或氯原子; R3独立地表示(i)氧代基,羟基,氨基,烷基氨基或羧基; (ii)具有3至8个碳原子的环烷基,所述环烷基被1至5个取代基取代,或(iii)具有3至8个原子的杂环基,所述杂环基未被取代或被1 至5个取代基,n为1,2或3,或其药学上可接受的盐。 这些化合物具有5-HT 4受体激动活性,因此可用于治疗哺乳动物特别是人类的胃食管反流病,非溃疡性消化不良,功能性消化不良,肠易激综合征等。
    • 6. 发明授权
    • Oxyindole derivatives
    • 氧吲哚衍生物
    • US07589109B2
    • 2009-09-15
    • US11360095
    • 2006-02-22
    • Chikara UchidaHiroki SoneKiyoshi Kawamura
    • Chikara UchidaHiroki SoneKiyoshi Kawamura
    • A61K31/454C07D403/14
    • C07D401/12C07D401/14C07D405/14
    • This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, R1, R2, R3, R4 and R5 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes or apnea syndrome.
    • 本发明涉及式(I)化合物或其药学上可接受的盐,其中:A,R 1,R 2,R 3,R 4和R 5各自如本文所述或其药学上可接受的盐,以及含有这些化合物的组合物和 使用这些化合物治疗由5-HT4激动活性介导的病症,例如但不限于胃食道反流病,胃肠道疾病,胃动力障碍,非溃疡性消化不良,功能性消化不良,肠易激综合征(IBS) ),便秘,消化不良,食道炎,胃食管疾病,恶心,中枢神经系统疾病,阿尔茨海默病,认知障碍,呕吐,偏头痛,神经系统疾病,疼痛,心血管疾病,心力衰竭,心律失常,糖尿病或呼吸暂停综合征。
    • 8. 发明授权
    • Benzisoxazole derivatives
    • 苯并异恶唑衍生物
    • US08816090B2
    • 2014-08-26
    • US11814588
    • 2006-02-15
    • Hirohide NoguchiIsao SakuradaChikara UchidaNobuaki Waizumi
    • Hirohide NoguchiIsao SakuradaChikara UchidaNobuaki Waizumi
    • C07D261/20A61K31/4439
    • C07D413/12C07D413/14
    • This invention relates to compounds of the formula (I): wherein A, B, R1, R4, m, and n are each as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central 10 nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.
    • 本发明涉及式(I)的化合物:其中A,B,R 1,R 4,m和n各自如本文所述或其药学上可接受的盐,以及含有这些化合物的组合物和这些化合物在 治疗由5-HT4受体活性介导的病症,例如但不限于胃食管反流病,胃肠道疾病,胃动力障碍,非溃疡性消化不良,功能性消化不良,肠易激综合征(IBS),便秘,消化不良,食管炎 ,胃肠疾病,恶心,中枢10神经系统疾病,阿尔茨海默病,认知障碍,呕吐,偏头痛,神经系统疾病,疼痛,心力衰竭和心律失常等心血管疾病,糖尿病和呼吸暂停综合征。
    • 9. 发明授权
    • 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity
    • 具有5-HT 4受体激动活性的1-异丙基-2-氧代-1,2-二氢吡啶-3-甲酰胺衍生物
    • US08362038B2
    • 2013-01-29
    • US12708012
    • 2010-02-18
    • Tomoki KatoKiyoshi KawamuraChikara Uchida
    • Tomoki KatoKiyoshi KawamuraChikara Uchida
    • A61K31/4545C07D401/12
    • C07D401/12C07D405/14
    • This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula —C(R4)(R5)— (in which R4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.
    • 本发明提供式(I)化合物:其中R 1表示具有1至4个碳原子的烷基或卤原子,R 2表示具有1至4个碳原子的烷基,R 3表示氢原子或羟基 基团,A表示氧原子或式-C(R4)(R5) - (其中R4表示氢原子或具有1至4个碳原子的烷基,R5表示羟基或式 具有1至4个碳原子的烷氧基)或其药学上可接受的盐。 这些化合物具有5-HT 4受体激动活性,因此可用于治疗哺乳动物特别是人类的胃食管反流病,非溃疡性消化不良,功能性消化不良,肠易激综合征等。
    • 10. 发明授权
    • Benzimidazolone compounds having 5-HT4 receptor agonistic activity
    • 具有5-HT 4受体激动活性的苯并咪唑酮化合物
    • US07776885B2
    • 2010-08-17
    • US10933629
    • 2004-09-02
    • Yasuhiro KatsuSatoru IguchiHiroki SoneChikara UchidaTakashi Kojima
    • Yasuhiro KatsuSatoru IguchiHiroki SoneChikara UchidaTakashi Kojima
    • A61K31/454C07D471/04
    • C07D413/14C04B35/632C07D401/12C07D405/06C07D405/14
    • This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.
    • 本发明提供式(I)化合物或其药学上可接受的盐,以及含有这些化合物的组合物以及这些化合物在制备胃食管反流疾病,胃肠道疾病,胃动力障碍,非溃疡的药物中的用途 消化不良,功能性消化不良,肠易激综合征(IBS),便秘,消化不良,食管炎,胃食管疾病,恶心,中枢神经系统疾病,阿尔茨海默病,认知障碍,呕吐,偏头痛,神经系统疾病,疼痛,心血管疾病,心力衰竭,心脏 心律失常,糖尿病和呼吸暂停综合征。 这些化合物具有5-HT 4受体激动活性,因此可用于治疗哺乳动物特别是人类的胃食管反流病,非溃疡性消化不良,功能性消化不良,肠易激综合征等。